The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region.
The perfusion systems market is segmented on the
basis of type (namely cardiopulmonary perfusion systems, ex vivo organ
perfusion systems, and cell perfusion systems) and region.
Perfusion
systems are used to bypass cardiopulmonary systems in order to treat
patients with cardiac and respiratory diseases surgically. Perfusion
systems such as heart-lung machines deliver oxygen and remove carbon
dioxide in patients when the heart and lungs fail to carry out the
process of blood oxygenation. With the increasing prevalence of
cardiovascular and respiratory diseases across the globe, the use of
perfusion systems is expected to rise in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164273069
Perfusion Systems Market Drivers
• Increasing prevalence of cardiovascular and respiratory diseases
• Rising number of organ transplantations
• Growth in Aging Population, Increasing Incidence of Multiple Organ Failures
• Government and NGO Initiatives to Encourage Organ Donation
• Increasing Investments in Cell-Based Research
• Increase in Biologic Manufacturing
Restraints
• High Cost of Organ Transplantation
• Ethical Concerns and High Cost of Cell-Based Research
Opportunities
• Increasing Pharmaceutical Research in Emerging Markets
• Rising Preference for Continuous Manufacturing
Challenges
• Organ Supply-Demand Gap
Increasing prevalence of cardiovascular and respiratory diseases
Cardiovascular
diseases are among the leading causes of death globally. They account
for about 9.4 million deaths every year. According to the WHO, in 2012,
17.5 million CVD-related deaths (31%) were reported across the globe;
this number is expected to grow to more than 23.6 million by 2030. Their
high prevalence is in part attributed to the rising prevalence of
hypertension, a key risk factor for cardiovascular disease and strokes.
In 2013, globally, it was estimated that about 1 billion people suffered
from hypertension—a global prevalence of 40%. During the same year, the
prevalence of hypertension among adults in Africa was 46% (highest
worldwide), while in the Americas, the figure was 35% (the lowest)
[Source: WHO]. Similarly, according to the WHO, chronic obstructive
pulmonary disease (COPD) caused about 3 million deaths (5%) of the total
deaths in 2015. COPD is expected to increase in the coming years due to
increasing tobacco consumption and growing pollution.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164273069
Major Market Developments:
•
In January 2015, Medtronic acquired Covidien plc. (Ireland), a
manufacturer of healthcare products for use in clinical and home
settings worldwide. This acquisition aims to strengthen Medtronic’s
customer base and resolve healthcare challenges with constant product
development and imbibing new technologies.
• In October 2015, Sorin merged with Cyberonics Inc (US) to form a global medical technology company—LivaNova PLC (U.K.).
•
In February 2014, Sorin acquired Bioengineering Laboratories S.p.A.
(BEL), a manufacturer of cardiac surgery cannulas. This acquisition is
expected to strengthen Sorin’s position in the cardiovascular cannulas
market segment.
• In September 2016, Terumo partnered with
CytoSorbents Corporation (US), a manufacturer of the CytoSorb
extracorporeal blood purification adsorber. Under this partnership,
Terumo commercialized the CytoSorb extracorporeal blood purification
adsorber for cardiac surgery applications in France, Sweden, Denmark,
Norway, Finland, and Iceland.